Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OK, Jabbour S, Rosenstock J
we help you manage potential side effects and monitor your progress
Restoring cellular energy is only half the battle
Tirzepatide (Zepbound) for weight loss The bottom line Tirzepatide (Zepbound) was approved in 2023 by the US Food and Drug Administration (FDA) for weight loss
There may be a role for microdosing in a few scenarios: When side-effects are not manageable: when side-effects are intolerable for patients, even on the lowest introductory dose, there may be a role for individualised approaches
Cagrilintide is not intended for human or veterinary use, treatment, diagnosis, supplementation, cosmetic application, or self-administration